| Literature DB >> 8986743 |
M Citron1, D Westaway, W Xia, G Carlson, T Diehl, G Levesque, K Johnson-Wood, M Lee, P Seubert, A Davis, D Kholodenko, R Motter, R Sherrington, B Perry, H Yao, R Strome, I Lieberburg, J Rommens, S Kim, D Schenk, P Fraser, P St George Hyslop, D J Selkoe.
Abstract
The mechanism by which mutations in the presenilin (PS) genes cause the most aggressive form of early-onset Alzheimer's disease (AD) is unknown, but fibroblasts from mutation carriers secrete increased levels of the amyloidogenic A beta 42 peptide, the main component of AD plaques. We established transfected cell and transgenic mouse models that coexpress human PS and amyloid beta-protein precursor (APP) genes and analyzed quantitatively the effects of PS expression on APP processing. In both models, expression of wild-type PS genes did not alter APP levels, alpha- and beta-secretase activity and A beta production. In the transfected cells, PS1 and PS2 mutations caused a highly significant increase in A beta 42 secretion in all mutant clones. Likewise, mutant but not wildtype PS1 transgenic mice showed significant overproduction of A beta 42 in the brain, and this effect was detectable as early as 2-4 months of age. Different PS mutations had differential effects on A beta generation. The extent of A beta 42 increase did not correlate with presenilin expression levels. Our data demonstrate that the presenilin mutations cause a dominant gain of function and may induce AD by enhancing A beta 42 production, thus promoting cerebral beta-amyloidosis.Entities:
Mesh:
Substances:
Year: 1997 PMID: 8986743 DOI: 10.1038/nm0197-67
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440